Peter Lebowitz, Third Arc Bio CEO
July 23, 2024 07:00 AM EDTUpdated August 20, 10:19 AM
Financing
Startups

At Third Arc Bio, for­mer J&J lead­ers raise $165M to test on­col­o­gy, au­toim­mune bi­o­log­ics

Kyle LaHucik

Senior Reporter

Af­ter more than a decade steer­ing John­son & John­son’s on­col­o­gy drug R&D, Pe­ter Lebowitz is ready for his next chal­lenge: shep­herd­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times